Ironwood Pharmaceuticals Inc. (IRWD)

IRWD (NASDAQ:Health Services)
$13.49
neg -0.34
-2.46%
Today's Range: 13.16 - 13.71 | IRWD Avg Daily Volume: 926,900
Last Update: 05/21/13 - 4:00 PM EDT
Volume: 2,296,284
YTD Performance: 29.87%
Open: $13.41
Previous Close: $13.83
52 Week Range: $10.01 - $19.67
Oustanding Shares: 108,766,210
Market Cap: 1,184,109,038
6-Month Chart
TheStreet Ratings Grade for IRWD
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 3 3 3 3
Moderate Buy 0 1 1 1
Hold 4 4 4 4
Moderate Sell 0 0 0 0
Strong Sell 3 2 2 2
Mean Rec. 3.00 2.65 2.65 2.65
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: -11.89
Price Earnings Comparisons:
IRWD Sector Avg. S&P 500
-11.89 0.00 17.70
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
3.90% 16.41% 9.93%
GROWTH 12 Mo 3 Yr CAGR
Revenue 128.10 3.16 0.60
Net Income 0.00 0.02 0.00
EPS 0.00 -0.93 0.00
Earnings for IRWD:
EBITDA -0.07B
Revenue 0.15B
Average Earnings Estimates
Qtr (06/13) Qtr (09/13) FY (12/13) FY (12/14)
Average Estimate $-0.72 $-0.65 $-2.81 $-1.63
Number of Analysts 7 7 8 7
High Estimate $-0.64 $-0.54 $-2.57 $-1.40
Low Estimate $-0.89 $-0.74 $-3.04 $-1.95
Prior Year $-0.38 $0.42 $-0.68 $-2.81
Growth Rate (Year over Year) -90.23% -254.08% -313.60% 41.94%
Update Chart
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
StadlerStocks
StadlerStocks: $IRWD hasn't closed under $13 since January. More than a little perplexing why the offering was priced so low. http://t.co/1ixww7NTeG
2 hours ago from web
Econtweeter
Econtweeter: Keeping a close eye on which institutions are adding Ironwood. #Speculation #M&A #biotech $IRWD
2 hours ago from Twitter for iPhone
teevee
teevee: Bounce Candidates for WED ... $RIG $SJM $IRWD CPB MSG PAMT PFE UNXL
4 hours ago from StockTwits Web
MikeOinSATX
MikeOinSATX: RT @SheffStation: $IRWD..Ironwood Pharmaceuticals Prices Public Offering of Common Stock at discount of $13/share. http://t.co/j1sXVp8VDP
7 hours ago from web
WallStreetPenni
WallStreetPenni: $heff: $IRWD..$13.00..Ironwood Pharmaceuticals Prices Public Offering of Common S http://t.co/zpBp0mt7hs
7 hours ago from dlvr.it
SheffStation
SheffStation: $IRWD..Ironwood Pharmaceuticals Prices Public Offering of Common Stock at discount of $13/share. http://t.co/j1sXVp8VDP
7 hours ago from bitly
theflynews
theflynews: $IRWD Ironwood 10.5M share Secondary priced at $13.00: Full Story http://t.co/rTjcYOl342
7 hours ago from twitterfeed
noodls_sHealth
noodls_sHealth: $IRWD Ironwood Pharmaceuticals Prices Public Offering of Common Stock http://t.co/I1mxV2zIh0
8 hours ago from noodlsHealthcareFeed
amitp_gupta
amitp_gupta: @23aloha @bradloncar Noticed $IRWD priced at $13
8 hours ago from Twitter for Android
BV_Healthcare
BV_Healthcare: $IRWD Ironwood Pharmaceuticals Prices Public Offering of Common Stock.. http://t.co/nPJgO2epTJ
8 hours ago from BoardVote.com

Watch for Negative Earnings Surprises

By

Gary Dvorchak

| Apr 26, 2013 | 11:00 AM EDT
The negative surprises indicate hidden weakness in a business, and the stocks are to be avoided.
Bearish
Ironwood Pharmaceutical downgraded at Wedbush
Apr 24, 2013 | 8:17 AM EDT
Shares of IRWD were downgraded to Underperform  from Neutral, said Wedbush. Cash burn is occurring much faster than expected given...
Bullish
Ironwood Pharmaceuticals upgraded at Credit Suisse
Mar 15, 2013 | 8:18 AM EDT
IRWD was upgraded to Outperform, Credit Suisse said. $24 price target. Expect higher Linzess sales. 
Bullish
Ironwood Pharmaceutical upgraded at Wedbush
Feb 13, 2013 | 8:38 AM EST
IRWD was upgraded to Neutral from Underperform, Wedbush said. $13 price target. LINZESS strong out of the gates. 
Bearish
Ironwood Pharmaceutical downgraded at UBS
Jan 16, 2013 | 8:39 AM EST
IRWD was downgraded to Sell from Neutral, UBS said. $11.50 price target. Expectations too high. 
Bearish
Ironwood Pharmaceuticals downgraded at Wedbush
Mar 05, 2012 | 8:19 AM EST
IRWD was downgraded to Underperform from Outperform, Wedbush said.  $8 price target.  Updated launch expenses leads to signif...
Bearish
Ironwood Pharmaceuticals downgraded at Cantor
Feb 29, 2012 | 7:15 AM EST
IRWD was downgraded to Sell, Cantor Fitzgerald said. Valuation call, based on a $10 price target.

Columnist Conversation / Market Updates

NetApp (NTAP): Storing Up Disappointment
By Chris Laudani
| May 21, 2013
| 5:33 PM EDT
Co misses on revenues. Revenue rose (if you can call it that) 0.8% to $1.7 bin. (I was looking for 1.7% y/y rev growth.)...
Making a late move on NTAP
By Robert Lang
| May 21, 2013
| 3:46 PM EDT
We added a call spread for NTAP here, not as pricey as the move implies, the chart not looking too bad. I like this for...
See all »

Our Tweets

BROKERAGE PARTNERS

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.